1. Home
  2. AGIO vs AGX Comparison

AGIO vs AGX Comparison

Compare AGIO & AGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • AGX
  • Stock Information
  • Founded
  • AGIO 2007
  • AGX 1961
  • Country
  • AGIO United States
  • AGX United States
  • Employees
  • AGIO N/A
  • AGX N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • AGX Engineering & Construction
  • Sector
  • AGIO Health Care
  • AGX Consumer Discretionary
  • Exchange
  • AGIO Nasdaq
  • AGX Nasdaq
  • Market Cap
  • AGIO 2.0B
  • AGX 2.1B
  • IPO Year
  • AGIO 2013
  • AGX N/A
  • Fundamental
  • Price
  • AGIO $33.23
  • AGX $185.46
  • Analyst Decision
  • AGIO Buy
  • AGX Buy
  • Analyst Count
  • AGIO 7
  • AGX 3
  • Target Price
  • AGIO $56.33
  • AGX $123.33
  • AVG Volume (30 Days)
  • AGIO 975.9K
  • AGX 333.0K
  • Earning Date
  • AGIO 02-13-2025
  • AGX 12-05-2024
  • Dividend Yield
  • AGIO N/A
  • AGX 0.81%
  • EPS Growth
  • AGIO N/A
  • AGX 92.83
  • EPS
  • AGIO 11.80
  • AGX 4.81
  • Revenue
  • AGIO $32,871,000.00
  • AGX $806,259,000.00
  • Revenue This Year
  • AGIO $33.41
  • AGX $47.84
  • Revenue Next Year
  • AGIO $172.14
  • AGX $6.90
  • P/E Ratio
  • AGIO $2.78
  • AGX $38.56
  • Revenue Growth
  • AGIO 36.79
  • AGX 52.83
  • 52 Week Low
  • AGIO $21.18
  • AGX $43.44
  • 52 Week High
  • AGIO $62.58
  • AGX $185.01
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 36.88
  • AGX 75.21
  • Support Level
  • AGIO $31.39
  • AGX $151.17
  • Resistance Level
  • AGIO $35.03
  • AGX $178.38
  • Average True Range (ATR)
  • AGIO 1.71
  • AGX 8.60
  • MACD
  • AGIO 0.54
  • AGX 3.77
  • Stochastic Oscillator
  • AGIO 39.91
  • AGX 99.48

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

About AGX Argan Inc.

Argan Inc is a United States-base construction firm that conducts operations through its wholly-owned subsidiaries, GPS, APC, TRC and SMC. Through GPS and APC it provides a full range of engineering, procurement, construction, commissioning, maintenance, project development and technical consulting services to the power generation market, including the renewable energy sector, for a wide range of customers, including independent power project owners, public utilities, power plant heavy equipment suppliers and other commercial firms with power requirements in the U.S., Ireland and the U.K. It operates in three segments: Power Services, Industrial Services, and Telecom Services, out of which Power Services derive majority revenue.

Share on Social Networks: